Italia markets closed

Anavex Life Sciences Corp. (AVXL)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
5,09+0,03 (+0,59%)
Alla chiusura: 04:00PM EDT
5,09 0,00 (0,00%)
Dopo ore: 05:13PM EDT

Anavex Life Sciences Corp.

630 5th Avenue
20th Floor
New York, NY 10111
United States
844 689 3939
https://www.anavex.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno40

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Christopher U. Missling M.B.A., M.S., Ph.D.President, CEO, Secretary & Director828,25k3,2M1966
Ms. Sandra Boenisch CPA, CGAPrincipal Financial Officer & Treasurer194,36kN/D1981
Mr. Stephan Toutain M.B.A., M.S.Senior VP of Operations & COON/DN/D1966
Dr. Walter E. Kaufmann M.D.Chief Scientific OfficerN/DN/DN/D
Clint TomlinsonVP of CorporateN/DN/DN/D
Dr. Adebayo Laniyonu Ph.D.Senior Vice President of Nonclinical DevelopmentN/DN/DN/D
Dr. Edward R Hammond M.D., M.P.H., Ph.D.Chief Medical OfficerN/DN/DN/D
Dr. Kun Jin Ph.D.Head of BiostatisticsN/DN/DN/D
Mr. David Goldberger R.Ph.Senior Vice President of Regulatory AffairsN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Governance aziendale

L'ISS Governance QualityScore di Anavex Life Sciences Corp. al 1 marzo 2024 è 4. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 3; diritti degli azionisti: 1; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.